E. Bernia's research while affiliated with Instituto Valenciano de Oncologia and other places

Publications (16)

Article
Resumen El manejo del carcinoma de células escamosas cutáneo (cSCC) avanzado es complicado, siendo modesta la eficacia de muchos de los fármacos sistémicos disponibles. Cemiplimab ha demostrado su eficacia en el tratamiento del cSCC avanzado en ensayos clínicos, pero los datos del mundo real siguen siendo limitados. Con el objetivo de evaluar la ef...
Article
Management of advanced cSCC is challenging, and many available systemic medications have modest efficacy. Cemiplimab has demonstrated efficacy in the treatment of advanced cSCC in clinical trials, but real-world data are still limited. With the objective of evaluating the efficacy of cemiplimab in a real-world clinical setting, we conducted a prosp...
Article
A man in his late 70s with stage IV adenocarcinoma of the lung presented with acute onset of redness, pain, and swelling of both lower limbs. The patient had received 4 cycles of chemotherapy with carboplatin, pemetrexed, and pembrolizumab for progressive disease and was currently in maintenance with pemetrexed-pembrolizumab. The edema appeared 5 d...
Article
A woman in her 70s was referred to the dermatology department for evaluation of chronic lymphedema of the right arm that had become painful over the preceding 2 weeks. The patient had a history of invasive ductal carcinoma that was treated 18 years earlier with mastectomy and regional lymphadenectomy, followed by adjuvant chemotherapy and radiother...
Article
Background Small series of ultrasound findings in dermatofibrosarcoma protuberans (DFSP) have been published, but the usefulness of this technique as a preoperative planning tool for tumor resection has not been studied. Materials and Methods We retrospectively reviewed patients with DFSP at our hospital that underwent ultrasound examination. Dept...
Article
Full-text available
Necrobiosis lipoidica is a rare chronic granulomatous disease. Multiple treatment approaches are available, but results are generally minimal and inconsistent. Some publications report variable results with photodynamic therapy (PDT) as a second line of treatment for refractory cases. We report 4 cases of necrobiosis lipoidica treated satisfactoril...
Article
Full-text available
Resumen La necrobiosis lipoidica (NL) es una enfermedad granulomatosa crónica poco frecuente para la que existen multitud de tratamientos disponibles. No obstante, estos ofrecen habitualmente mínimos e inconsistentes resultados. En algunas publicaciones se describe el tratamiento con terapia fotodinámica (TFD) como tratamiento de segunda línea en c...
Article
Background: There are no large series describing cutaneous histologic changes during treatment with vismodegib in locally advanced basal cell carcinoma (BCC). Objective: To analyze histologic changes in skin biopsy specimens from patients with locally advanced BCC treated with vismodegib. Methods: A descriptive, retrospective study of patients...
Article
Introduction and objectives Vismodegib is the first selective Hedgehog inhibitor approved for the treatment of locally advanced and metastatic basal cell carcinoma (BCC). In this article, we describe our experience with the use of this drug to treat advanced and/or multiple BCCs at a cancer center over 5 years. Material and methods We analyzed the...
Article
We designed a prospective, randomized, intraindividual, investigator‐blinded clinical trial comparing methyl‐5‐aminolaevulinate (MAL) cream and 5‐aminolaevulinic acid nanoemulsion (BF‐200 ALA) in the treatment of actinic keratosis (AK) with photodynamic therapy (PDT). Eligible patients had to have two symmetric, comparable areas of skin (left and r...
Article
Introduction and objectives: Vismodegib is the first selective Hedgehog inhibitor approved for the treatment of locally advanced and metastatic basal cell carcinoma (BCC). In this article, we describe our experience with the use of this drug to treat advanced and/or multiple BCCs at a cancer center over 5 years. Material and methods: We analyzed...

Citations

... eruptive nevi, serpentine supravenous hyperpigmentation, flagellate or reticulate hyperpigmentation, melanonychia, and post-inflammatory hyperpigmentation (associated with repeated trauma, toxic erythema of chemotherapy, etc.). 6,10,14 Although post-inflammatory hyperpigmentation following a phototoxic reaction induced by chemotherapeutic agents such as 5-FU, tegafur, vinblastine, dacarbazine, and doxorubicin can occur in some cases, 6 localized or more diffuse hyperpigmentation after UVA/UVB exposure can also develop progressively without an initial inflammatory phase. These lesions are most prevalent in areas regularly exposed to UVA and UVB light, notably the dorsal aspect of the hands (Fig. 1c) and the face. ...
... Для лечения местно-распространенного неоперабельного или метастатического базальноклеточного рака кожи успешно применяется препарат из группы ингибиторов сигнального пути Hedgehog висмодегиб. Однако, согласно результатам нескольких исследований, описана связь между применением препарата и развитием вторичного лекарственно-индуцированного ПКРК, а также плоскоклеточной метаплазии [31,32]. Предполагаемый механизм развития висмодегибассоциированного рака заключается в активации внутриклеточных сигнальных каскадов RAS/MAPK, которые задействованы в развитии ПКРК [33]. ...
... Vismodegib is an oral inhibitor of hedgehog pathway, approved for locally advanced and metastatic BCC in patients who are not amenable to surgery or radiation (5)(6)(7)(8)(9). Some fieldpractice experiences have evaluated the use of vismodegib for the treatment of BCC in daily practice (10)(11)(12)(13)(14)(15). However, the description of a further series of patients will help towards a more comprehensive evaluation of this treatment. ...
... El vismodegib y el sonidegib son ejemplos de medicamentos de terapia dirigida que se pueden usar para tratar algunos cánceres de piel de células basales avanzados o recurrentes. 71 Resulta muy poco común que los cánceres de células basales alcancen una etapa avanzada, pero si lo hacen, estos cánceres pueden ser difíciles de tratar. La mayoría de los cánceres de células basales tienen mutaciones en los genes que son parte de una vía de señalización celular llamada hedgehog. ...
... However, 7 days after the first PDT procedure, the intensity of pain was significantly lower in the areas treated with MAL-HCl or ALA-P (1.4 and 1.3 on average, respectively) than in the areas treated with ALA-HCl (1.8 on average). In most of the studies, patients reported more acute pain at the site of ALA-HCl application [20,[34][35][36][37][38][39]. However, in the reports by Yazdanyar et al., who compared the pain response to ALA-HCl and MAL treatment of the scalp and forehead AK lesions, no significant differences in pain intensity between these two formulations were found either during or 30 min after the completion of treatment [40]. ...